Home > Clinical Trials
Check All Search

Saved trials

RECRUITING
NCT06429761
Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian Patients
100 Enrollment(s)
4 Study location(s)
INTERVENTIONAL (PHASE4)
BREAST CANCER
RECRUITING
NCT05633979
Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer
37 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE1)
Breast Cancer
NOT_YET_RECRUITING
NCT07086768
Dose-Escalation and Dose-Expansion Study of BSI-082 Monotherapy and Combined Therapy in Patients With Advanced or Metastatic Solid Tumors
57 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE1)
Solid Tumor


Advanced Solid Tumor


Metastatic Solid Tumor
RECRUITING
NCT06311214
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
500 Enrollment(s)
8 Study location(s)
INTERVENTIONAL (PHASE2)
Advanced Malignant Solid Neoplasm


Metastatic Malignant Solid Neoplasm
RECRUITING
NCT06210776
A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
800 Enrollment(s)
54 Study location(s)
OBSERVATIONAL (None)
HER2-positive Breast Cancer


HER2-low Breast Cancer


Breast Cancer


Advanced Cancer
TERMINATED
NCT05744375
Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab
2 Enrollment(s)
19 Study location(s)
INTERVENTIONAL (PHASE2)
Locally Advanced Breast Cancer


Metastatic Breast Cancer
RECRUITING
NCT05573893
PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan
800 Enrollment(s)
101 Study location(s)
OBSERVATIONAL (None)
Breast Neoplasms


Breast Cancer


Neoplasm Metastasis
RECRUITING
NCT06467357
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
620 Enrollment(s)
254 Study location(s)
INTERVENTIONAL (PHASE3)
Biliary Tract Cancer